INTRODUCTION {#sec1-1}
============

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, characterized by auto-antibody production, complement activation, and immune complex deposition.[@ref1] Auto-antibodies mediate inflammation and various organs damaged through immune complex formation.[@ref2] We already knew that many factors such as infection environment, immunity and many other factor are closely related to cause this disease that adaptive immune system has been the focus of many studies.[@ref3] Current treatment strategies rely heavily on corticosteroids. This in turn leads to a cascade of events including increase in infections and malignancies, limit in immunosuppressives, long standing over reliance on corticosteroid therapy.[@ref4] Currently available treatment has involved the use of anti-inflammatory or immunosuppressive non-steroidal anti-inflammatory drugs to deal with different situation.[@ref5] This conventional treatment can be associated with organ damage and not completely effective in many patients, which highlighting a huge need in the area of SLE therapeutics.[@ref6]

In recent years, an increased understanding of the etiopathogenesis has led to development of biologic agents for SLE has been pressing, which may significantly improve the task of treating SLE.[@ref5] Among the biologic agents (atacicept, belimumab, blisibimod, epratuzumab, rituximab, tabalumab) for SLE, it is important to evaluate the efficacy of six biologic agents by systematic review and meta-analysis. Although the efficacy of the multiple biologic agents which used to treat SLE was acceptable, there was no direct comparison between the two interventions. Network meta-analysis (NMA) was an upgrade from traditional meta-analysis (TMA). This study may improve a useful guide for selection of medication treatments for SLE.

METHODS {#sec1-2}
=======

Search strategy: {#sec2-1}
----------------

The databases searched for this study included PubMed, EMBASE and Cochrane Library, before 4^th^ September 2018, using atacicept, belimumab, blisibimod, epratuzumab, rituximab or tabalumab and SLE. Through literature traceability, we read relevant reviews to view their references and other ways to trap, as much as possible to find all relevant information.

Inclusion and exclusion criteria: {#sec2-2}
---------------------------------

The inclusion criteria were as following:

a\. Randomized controlled trialsb. Both the experimental group and the control group were SLE patientsc. Data acquisition in around 52 weeksd. The data of efficacy or adverse reactions are complete and can be analyzed by NMAe. Document language was English.

The exclusion criteria were as following:

a\. Animal experiments, cross-experimental studiesb. Case reports, systematic reviewsc. Comparison before and after drug treatment, or no data available for analysisd. The patients with other disease included LN.

Efficacy evaluation criteria: {#sec2-3}
-----------------------------

Outcome indicators included SRI-4, SRI-6, because of different situations.

The SRI-4 was defined as the following:

a\. ≥ 4-point reduction in SELENA-SLEDAI score compared with baselineb. No worsening (\<0.3-point increase from baseline) in Physician's Global Assessment (PGA)c. No new British Isles Lupus Assessment Group (BILAG) A organ domain score or two new BILAG B organ domain scores vs baseline).

The SRI-6 was defined as the following:

a\. ≥6-point reduction in SELENA-SLEDAI score compared with baselineb. No worsening (\<0.3-point increase from baseline) in Physician's Global Assessment (PGA)c. No new British Isles Lupus Assessment Group (BILAG) A organ domain score or two new BILAG B organ domain scores vs baseline).

All analyses were adapted from previous published work. Thus, no ethical approval and patient consent were required.

Data extraction and quality evaluation: {#sec2-4}
---------------------------------------

Literature search and extraction were performed independently by two reviewers, based on the inclusion and exclusion criteria, include the following:

a\. Characteristics of the publicationb. Data quality of the publicationc. Result indicator selection.

Statistical analysis: {#sec2-5}
---------------------

By using commands of the network package in statistical (13.0), the network, evidence contribution, predictive interval (PrI), funnel and ranking plots were constructed. The efficacy of the intervention was ranked based on the surface values under the cumulative ranking (SUCRA) curve. The selected indicator was the count data, and *OR* is used as the combined effect, with a confidence interval (*CI*) set to 95%. A value of *P* \< 0.05 was considered to be statistically significant.

RESULTS {#sec1-3}
=======

A total of 21 RTCs involving 12276 patients were ultimately included in this study. [Fig. 1](#F1){ref-type="fig"} show the select detail of publication includes. The basic characteristics of publications are presented in [Table-I](#T1){ref-type="table"}.

###### 

Basic information of included studies in the network meta-analysis.

  Medicine      Author                     Country of patients                                                                                                                         A     B     C     D      E     F     G     During (weeks)   outcome   Jadad quality score
  ------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ----- ----- ----- ------ ----- ----- ----- ---------------- --------- ---------------------
  Belimumab     Ronald F van Vollenhoven   Sweden, USA, Spain, UK                                                                                                                      287   589                                  52               1         3
  Belimumab     A Doria                    USA, Europe, Asia                                                                                                                           141   435                                  52               1         4
  Belimumab     Fengchun Zhang             China, Japan, Soutd Korea                                                                                                                   217   446                                  52               1         4
  Belimumab     RICHARD A. FURIE           UK, USA                                                                                                                                     86    235                                  52               1         3
  Belimumab     A. Doria                   USA, Italy, Japan, Brazil, Netderlands, Nortd Carolina                                                                                      108   248                                  52               1         4
  Belimumab     Yoshiya Tanaka             Japan                                                                                                                                       20    39                                   52               1         4
  Belimumab     Richard Furie              Asia, USA, Europe                                                                                                                           275   544                                  52               1         4
  Belimumab     Susan Manzi                USA, Canada, Italy, Mexico                                                                                                                  287   589                                  52               1         3
  Belimumab     Ellen M                    USA                                                                                                                                         86    235                                  52               1         4
  Belimumab     William Stohl MD           USA, Europe, Australia and Asia                                                                                                             280   556                                  52               1         4
  Belimumab     Vibeke Strand              USA, UK, Spain, Brazil,                                                                                                                     287   578                                  52               1         2
  Atacicept     Joan T. Merrill            Latin America, Asia, Soutd Africa, Europe, UK, USA                                                                                          100         206                            52               1         3
  Epratuzumab   Megan E. B. Clowse         Nortd America, Latin America, Europe, tde Middle East, India, Korea, China                                                                  512               1017                     52               1         4
  Epratuzumab   Daniel J Wallace           USA, UK, China                                                                                                                              38                189                      52               1         4
  Epratuzumab   Daniel J. Wallace          USA,UK                                                                                                                                      40                65                       52               1         4
  Tabalumab     D A Isenberg               USA, Asian                                                                                                                                  381                      757               52               1         4
  Tabalumab     J T Merrill                USA, Canada, Mexico, Central America, Soutd America, Asia-Pacific, Africa/Middle East Europe                                                376                      752               52               1         4
  Tabalumab     Yoshiya Tanaka             Japanese                                                                                                                                    15                       15                52               1         4
  Rituximab     JT Merrill                 UK,USA                                                                                                                                      88                             169         52               1         3
  Blisibimod    Joan T Merrill             Belarus, Brazil, Colombia, Georgia, Guatemala, China, Korea, Singapore, Malaysia, Mexico, Russia, Sri Lanka, Thailand and the Philippines   197                                  245   52               2         4
  Blisibimod    R A Furie                  Argentina , Brazil, Chile, Colombia, China, India, Mexico, Peru, the Philippines, USA                                                       269                                  277   52               2         4

1: SIR4; 2: SIR6. Placebo: A; Belimumab: B; Atacicept: C; Epratuzumab: D; Tabalumab: E; Rituximab: F; Blisibimod: G.

![The selection details of included publications.](PJMS-35-1680-g001){#F1}

Network meta-analysis {#sec2-6}
---------------------

*Network plot of six different medicines:* Of the 21 publications studies on the biologic agents for SLE with belimumab were the most frequent, while those on atacicept and rituximab were least. The highest number of subjects was belimumab, while atacicept has the lowest number of this studies ([Fig. 2](#F2){ref-type="fig"}). The size of the points in the network graph is proportional to the number of subjects, while the thickness of the line is proportional to the number of studies.

![Network plot of different targeted therapies for the treatment of SLE\
***Abbreviations:*** Placebo: A, Belimumab: B, Atacicept: C, Epratuzumab: D, Tabalumab: E, Rituximab: F, Blisibimod: G](PJMS-35-1680-g002){#F2}

Evidence contribution plot {#sec2-7}
--------------------------

The direct comparison of placebo alone and belimumab had a 100% effect on the combined results. The direct comparison between placebo and belimumab had a 50% effect on the indirect comparison between belimumab and atacicept. The direct comparison of placebo and belimumab had a 16.7% effect on the results of the NMA ([Fig. 3](#F3){ref-type="fig"}).

![The effect of comparing the results of different control measures.\
***Abbreviations:*** Placebo: A, Belimumab: B, Atacicept: C, Epratuzumab: D, Tabalumab: E, Rituximab: F, Blisibimod: G](PJMS-35-1680-g003){#F3}

Predictive interval plot {#sec2-8}
------------------------

In this study, it is showed that the pooled *OR* and 95% *CI* of SLE improvement compared with placebo were 2.03 (1.38-3.00) for belimumab, 1.61 (0.44-5.84) for atacicept, 1.77 (0.80-3.88) for epratuzumab, 1.62 (0.73-3.57) for tabalumab, 1.56 (0.42-5.87) for rituximab, 1.08 (0.44-2.61) for blisibimod, respectively, which indicates an insignificant difference in efficacy except for belimumab. The comparison between other medicines is showed in [Fig. 4](#F4){ref-type="fig"}.

![Network estimates of mean *OR*, their 95% *CIs* and prediction intervals (red extensions)\
***Abbreviations:*** Placebo: 1, Belimumab: 2, Atacicept: 3, Epratuzumab: 4, Tabalumab: 5, Rituximab: 6, Blisibimod: 7](PJMS-35-1680-g004){#F4}

Publication bias {#sec2-9}
----------------

Regarding publication bias, all results in the study are basically symmetrical ([Fig. 5](#F5){ref-type="fig"}). The probability distribution for each treatment is ranked for their efficacy in SLE according to SUCRA values ([Table-II](#T2){ref-type="table"} and [Fig. 4](#F4){ref-type="fig"}). The order of SUCRA values for different biologic agents was as follows: belimumab (75.0); epratuzumab (62.0); tabalumab (57.1); atacicept (55.1); rituximab (52.6); blisibimod (29.4) placebo (18.7); From this study, the belimumab had the highest probability of being the best treatment in biologic agents.

###### 

SUCRA of SLE treatments.

  Treatment     SUCRA (%)   Pr Best   Mean Rank
  ------------- ----------- --------- -----------
  Belimumab     75          20.9      2.5
  Epratuzumab   62          17.2      3.3
  Tabalumab     57.1        13.1      3.6
  Atacicept     55.1        24.1      3.7
  Rituximab     52.6        21.7      3.8
  Blisibimod    29.4        3         5.2
  Placebo       18.7        0         5.9

![Funnel plot for publication bias of different medicines.](PJMS-35-1680-g005){#F5}

![SUCRA for the cumulative probabilities.\
***Abbreviations:*** Placebo: 1, Belimumab: 2, Atacicept: 3, Epratuzumab: 4, Tabalumab: 5, Rituximab: 6, Blisibimod: 7](PJMS-35-1680-g006){#F6}

DISCUSSIONS {#sec1-4}
===========

The study analyzed six biologic agents for SLE in 21 randomized controlled trials. These results showed that the belimumab had the highest probability of being the best treatment compared with other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab), according to network meta-analysis by network diagram makes it more intuitive. Belimumab was more effective highest SUCRA value and highest probability of being the best treatment option, while other medicines indicated an insignificant difference in efficacy.

The SLE is caused by immune complexes depositing on organs and extensive injury were caused.[@ref7] The patients with SLE are characterized by BCR-initiated signaling and IL-6 production, including alter in B cell subset distribution.[@ref8] Therefore, the main clinical strategy for treating SLE was blocking the immune cells stimulating cytokine that affects the development of SLE. The main goal of current treatment strategies, which are not ideal in terms of efficacy and safety, was to use a limited dose of corticosteroids to prevent injury and maintain stable disease control.[@ref9]-[@ref11] Biologic agents are being developed to enhance therapeutic efficacy, reduce disease exacerbation and toxicities. Currently, drugs for the SLE treatment evolved from all the patients recommended antimalarial to nonsteroidal anti-inflammatory drugs, glucocorticoids and combination of biologic agents.

It was divideded into nine kinds according to its mechanism of action on the following:

a\. B cell therapies;b. Proteasome inhibitors;c. Inhibition of B/T cell costimulation;d. Targeting Pdc;e. Targeting cytokines and their receptors;f. Targeting the interferons;g. Targeting the kinases of the intracellular machinery;h. Targeting the sphingosine-1-phosphate;i. Other mechanisms of action.[@ref12]

This study analyzed six kinds of biologic agents (atacicept, belimumab, blisibimod, epratuzumab, rituximab, tabalumab), belonging to B cell therapies, to exclude classical immunosuppressive agents, and belimumab may be the most effective.

Belimumab is recombinant human immunoglobulin (Ig) G1-λmAb, which molecular weight of \~147 kDa.[@ref13] It specifically binds to soluble B-lymphocyte stimulator (BLyS), prevents its interaction with other receptors, inhibits B cell apoptosis, stimulates B cells to differentiate into immunoglobulins.[@ref14] BlyS and its receptors (TACI, BCMA and BAFF-R) remain the focal point of therapeutic targets for SLE therapy as autoimmune B cell stimulation and maturation play a major role in the disease onset.[@ref15] In mouse models of systemic lupus erythematosus, BLyS inhibition delays lupus onset, while in clinical trials, belimumab reduces the number of peripheral CD20 + B cells, which is predominantly naive, significantly reduces SLE disease activity, flare rates and prednisone dose in seropositive patients.[@ref16]-[@ref18]

In this study, we focused on SIR response, while adverse reactions also occurred in clinical trials, including headache, fever, nausea, diarrhea and other side effect. The causes of deaths include serious infections, heart disease and suicide. Hypersensitivity reactions may occur, such as immediate withdrawal, and appropriate treatment.[@ref19]

In addition, the biologic agents except for belimumab (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) were insignificantly superior to placebo. These approaches biologic agents of B cell therapies include: block BLyS, modulate B cell signaling, neutralise soluble BLyS, induce depletion of B cells, block with all three forms of BLyS.[@ref20]-[@ref24] The causes of the results are unclear, while biologic agents in treatment of systemic lupus erythematosus are still a long way to go whatever in safe or efficacy.

Limitations of study: {#sec2-10}
---------------------

In this study, the lack of uniform standards for efficacy evaluation and inconsistent quality of the original publication used may have some effect on the strength of the proposed argument. The results may be affected by inconsistently literature quality, great heterogeneity inherent to SLE, different ethnicity and sample size. Future studies involving high quality RCT and large sample size are needed.

CONCLUSIONS {#sec1-5}
===========

Biologic agents except for belimumab (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) indicated an insignificant difference in efficacy for the treatment of SLE compared with placebo. Belimumab had the highest probability of being the best treatment for SLE compared with the other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab).
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